Mosaic Therapeutics Secures £261.4k Growth Funding Amidst Evolving UK Biotech Landscape

Mosaic Therapeutics Limited, an oncology therapeutics company based in Babraham, has successfully secured £261.4k in a recent growth funding round. The funding, with an allotment date of 5 December 2025 and filed on 23 April 2026, marks a new injection of capital for the company focused on developing targeted drug combinations for cancer.

Founded on 30 July 2020, Mosaic Therapeutics addresses cancers with substantial unmet needs by identifying novel biomarker-defined patient populations most likely to respond to their treatments. The company's mission is rooted in reinventing traditional approaches to target and drug discovery, leveraging a differentiated dual technology platform to advance novel combination therapies. This platform emerged from pioneering research conducted at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, benefiting from 20 years of refinement and development. Mosaic Therapeutics currently has active programmes across various oncology indications and disease biology pathways.

The company's latest financial accounts indicate a profit/loss of £-7,583,472 and a team of 23 employees. Its LinkedIn profile corroborates its focus on biotechnology research, listing 22 employees and specialties including oncology, tumour agnostic therapies, genomics, organoids, targeted combination therapy, drug discovery, drug development, precision medicine, and machine learning.

This most recent growth round of £261.4k follows several larger funding rounds for Mosaic Therapeutics. The company previously raised £10.5m in a Series A round on 10 April 2025, £7.7m in an unspecified round on 6 August 2024, and an earlier Series A round of £10m on 17 October 2022. The current funding round is notably smaller than these previous capital raises.

In terms of leadership, Thomas Fuchs was appointed as a director on 31 October 2025.

The funding landscape for UK biotech companies, particularly in the oncology sector, has experienced a period of adjustment. In 2025, the UK biotech sector secured £1.9 billion in equity financing, with venture capital accounting for £1.79 billion across 58 deals, representing a 13.2% decrease year-on-year compared to 2024. Despite this overall decline, the UK maintained its position as Europe's leading national biotech market, attracting 30% of all European venture financing.

Investor caution characterised much of 2025, with capital often concentrated in a limited number of larger transactions. For instance, two significant Q1 transactions in 2025, involving Isomorphic Labs and Verdiva Bio, accounted for a substantial share of the total capital raised, elevating the average deal size to around £30.8 million from £18.7 million in 2024. However, the median deal size in 2025 saw a decline to £5.5 million from £8.9 million, suggesting that typical rounds were smaller and capital distribution was less even.

Towards the end of 2025, there was a notable shift, with the fourth quarter recording 22 completed deals, the highest quarterly deal count of the year, indicating renewed investor confidence heading into 2026. However, early-stage biotech funding faced a squeeze in the first quarter of 2026, as investors continued to favour later-stage firms with clearer data, lower risk, and faster paths to exits.

Government initiatives also play a role in supporting the sector. UK Research and Innovation (UKRI) has a Cancer Therapeutics programme with a £30 million budget over three years, aimed at accelerating the commercialisation of cancer therapies discovered in UK universities and businesses. This programme supports accelerators, venture creation for early-stage SMEs and academic spin-outs, industry-led research and development, and investor partnerships. This broader ecosystem support underscores the strategic importance of companies like Mosaic Therapeutics in advancing cancer treatment.